tao-liu
Tao Liu, BMed, MMed, PhD
Lowy Cancer Research Centre

University of New South Wales
Randwick, New South Wales, Australia
Phone: +61 (2) 9385 1935
E-mail: tliu@ccia.unsw.edu.au

Education

BMed 1982-1987 Suzhou Medical College, Suzhou University, China
MMed 1987–1990 Shanghai Medical University, China
PhD 1998-2000 University of New South Wales, Sydney, New South Wales, Australia

Biography

Originally trained as a medical practitioner specialising in neurology, Dr Tao Liu studied for a PhD degree at The University of New South Wales, Sydney, Australia on the role of inflammatory mediators in chronic pain due to nerve injury. He then worked on the role of MIC-1, a new member of the transforming growth factor beta superfamily, in cancer cell proliferation, survival/apoptosis and metastasis at St. Vincent's Centre for Applied Medical Research, Sydney, Australia.

Dr Liu joined Children's Cancer Institute Australia for Medical Research as a Senior Research Officer in 2003. Since 2004, he has been focusing his research on the roles of histone deacetylases, histone demethylases, histone methyltransferases and long noncoding RNAs in modulating gene transcription and tumourigenesis, and the roles of histone deacetylase inhibitors and histone methyltransferase inhibitors as anticancer agents. He was promoted to Project Leader in 2009 and Group Leader in 2011.


Research Interest

Keywords

Cancer, carcinogenesis, epigenetics, histone modification, gene expression, noncoding RNA, metastasis, drug discovery, experimental therapy

Interests
  1. Transcriptional modulation of oncogene and tumour suppressor gene expression by histone deacetylases, histone demethylases and histone methyltransferases.
  2. The roles of histone deacetylases, histone demethylases and histone methyltransferases in the initiation and progression of cancer.
  3. The anticancer efficacy of histone deacetylase inhibitors and histone methyltransferase inhibitors in cancer cell lines and animal models.
  4. Discovery of novel histone methyltransferase inhibitors for the therapy of cancer
  5. Identification of the mechanisms important for the stability and/or degradation of Myconcoproteins, the most commonly de-regulated oncoprotein in human cancers.
  6. Long noncoding RNAs as critical modulators of chromatin function and gene expression.
  7. Long noncoding RNAs as novel targets for cancer therapy
Broad Research Areas
  1. Molecular and cellular biology
  2. Chromatin modification
  3. Gene transcription
  4. Genomics and epigenetics
  5. Drug discovery
  6. Experimental cancer therapy

Scientific Activities

  1. Member,  American Association for Cancer Research
  2. Editor, International Journal of Clinical and Experimental Medicine
  3. Editor, World Journal of Biological Chemistry
  4. Editor, Epigenetics & Genomics

Publications

  1. Melaiu M, Mina M, Chierici M, Boldrini R, Jurman G, Romania P, D’Alicandro V, Benedetti MC, Castellano A, LIU T, Furlanello C, Locatelli F, and Fruci D. PD-L1 is a therapeutic target of the Bromodomain inhibitor JQ1 and, combined with HLA class I, a promising prognostic biomarker in neuroblastoma. Clin Cancer Res, 2017; (accepted March 1) (impact factor: 8.738)                                                 
  2. Wong MK, Tee AE, Milazzo G, Bell JL, Poulos RC, Atmadibrata B, Sun Y, Jing D, Ho N, Ling D, Liu PY, Zhang XD, Hüttelmaier S, Wong JW, Wang J, Polly P, Perini G, Scarlett CJ, and LIU T. The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription. Cancer Res, 2017 (accepted Feb. 14) 
  3. Tang Y, Cheung BB, Atmadibrata B, Marshall GM, Dinger ME, Liu PY, and LIU T. The regulatory role of long noncoding RNAs in cancer. Cancer Letters, 2017; 391:12-19 (impact factor: 5.992)      
  4. Jung M, Russell AJ, Liu B, George J, Liu PY, LIU T, DeFazio A, Bowtell DDL, Oberthuer A, London WB, Fletcher JI, Haber M, Norris MD, and Henderson MJ. A Myc activity signature predicts poor clinical outcomes in Myc-associated cancers. Cancer Res, 2017; 77(4): 971-981 (impact factor: 8.556)
  5. Liu PY, Atmadibrata B, Mondal S, Tee AE, and LIU T. NCYM is up-regulated by lncUSMycN and modulates N-Myc expression. Int J Oncol, 2016; 49 (6); 2464-2470 (impact factor: 3.018)    
  6. Liu PY, Sokolowski N, Guo ST, Atmadibrata B, Siddiqi F, Telfer TJ, Sun Y, Zhang L, Yu D, McCarroll J, Liu L, Yang RH, Guo XY, Tee AE, Itoh K, Wang J, Kavallaris M, Haber M, Norris MD, Cheung BB, Byrne JA, Ziegler DS, Marshall GM, Dinger ME, Codd R, Zhang XD, and LIU T. The BET bromodomain inhibitor exerts the best synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs. Oncotarget, 2016; (ePub Sept 27). (Impact factor: 5.008)                          
  7. Xue C, Yu DMT, Gherardi A, Koach J, Milazzo G, Gamble L, Liu B, Valli E, Russell AJ, London WB, LIU T, Cheung BB, Marshall GM, Perini G, Haber M, and Norris MD. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4. Oncotarget, 2016; 7(34): 54937-54951(impact factor: 5.008)
  8. Guo ST, Chi MN, Yang RH, Guo XY, Zan LK, Wang CY, Xi YF, Jin L, Croft A, Tseng H-Y, Yan XG, Farrelly M, Wang FH, Lai F, Wang JF, Li YP, Ackland S, Scott R, Agoulnik IU, Hondermarck H, Thorne RF, LIU T, Zhang XD, and Jiang CC. INPP4B is an oncogenic regulator in human colon cancer.Oncogene, 2016;35 (23): 3049-3061(impact factor: 7.932)                                                                         
  9. Xi Z, Yao M, Li Y, Xie C, Holst J, LIU T, Cai S, Lao Y, Tan H, Xu HX, and Dong Q. Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation. Cell Death & Disease, 2016;7(6): e2252 (impact factor: 5.378)                
  10. Kim PY, Tan O, Liu B, Trahair T, LIU T, Haber M, Norris MD, Marshall GM, and Cheung BB. High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients. Cancer Letters, 2016; 374(2): 315-323 (impact factor: 5.992)  
  11. Lynch J, Yi H, Casolari D, Voli F, Gonzales-Aloy E, Fung TK, Liu B, Brown A, LIU T, Haber M, Norris M, Lewis I, So CWE, D'Andrea R, and Wang JY. Gaq signaling is required for the maintenance of MLL-AF9 induced AML. Leukemia, 2016; (ePub Feb 26)(impact factor: 12.104)                                   
  12. Shahbazi J, Liu PY, Atmadibrata B, Bradner JE, Marshall GM, Lock RB, and LIU T.The bromodomain inhibitor JQ1 and the histone deacetylase inhibitor panobinostat synergistically reduce N-Myc expression and induce anticancer effects. Clin Cancer Res,2016;22(10): 2534-2544 (impact factor: 8.738)   
  13. Tee AE, Liu B, Song R, Li J, Pasquier E, Cheung BB, Jiang C, Marshall GM, Haber M, Norris MD, Fletcher JI, Dinger ME, and LIU T. The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression. Oncotarget,2016; 7(8): 8663-8675  (impact factor: 5.008)                             [Cit 1]
  14. Carter DR, Murray J, Cheung BB, Gamble L, Koach J, Tsang J, Sutton S, Kalla H, Syed S, Gifford AJ, Issaeva N, Biktasova A, Atmadibrata B, Sun Y, Sokolowski N, Ling, D, Kim PY, Webber H, Clark A, Ruhle M, Liu B, Oberthuer A, Fischer M, Byrne J, Saletta F, Thwe le M, Purmal A, Haderski G, Burkhart C, Speleman F, De Preter K, Beckers A, Ziegler DS, LIU T, Gurova KV, Gudkov AV, Norris MD, Haber M, and Marshall GM. Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Sci Transl Med,2015;7(312): 312ra176 (impact factor: 16.264)                             [Cit 4]
  15. Sun Y, Bell JL, Carter DR, Gherardi S, Poulos RC, Milazzo G, Wong JW, Al-AwarR, Tee AE, Liu, PY, Liu B, Atmadibrata B, Wong M, Trahair T, Zhao Q, Shohet JM, Haupt Y, Schulte JH, Brown PJ, Arrowsmith CH, Vedadi M, MacKenzie KL, Hüttelmaier S, Perini G, Marshall GM, Braithwaite A, and LIU T. WDR5 supports an N-Myc transcriptional complex that drives a pro-tumorigenic gene expression signature in neuroblastoma. Cancer Res,2015;75(23): 5143-5154 (impact factor:8.556)                            [Cit 2]
  16. Wong M, Polly P, and LIU T. The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target. Am J Cancer Res,2015;5(9): 2823-2837(impact factor: 3.425)                            [Cit 1]
  17. Chi MN,Guo ST, Wilmott JS, Guo XY, Yan XG, Wang CY, Liu XY, Jin L, Tseng H-Y, LIU T, Croft A, Scolyer RA,Zhang XD, and Jiang CC. INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. Oncotarget, 2015; 6(37): 39891-39907(impact factor: 5.008)                            [Cit 2]
  18. Cheung BB, Tan O, Koach J, Liu B, Shum MS, Carter DR, Sutton S, Po'uha ST, Chesler L, Haber M, Norris MD, Kavallaris M, LIU T, O'Neill GM, and Marshall GM. Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma. Mol Oncol, 2015; 9(7): 1484-1500(impact factor: 5.367)                              [Cit 2]
  19. Bell JL,Turlapati R, LIU T, Schulte JH, and Hüttelmaier S.IGF2BP1 harbors prognostic significance by gene gain, diverse expression and promotion of MYCN, in neuroblastoma. J Clin Oncol,2015;33(11): 1285-1293 (impact factor: 20.982)                             [Cit 2]
  20. Song R, Liu Q, LIU T, and Li J. Connecting rules from paired miRNA and mRNA expression data sets of HCV patients to detect both inverse and positive regulatory relationships. BMC Genomics,2015; 16(Suppl 2): S11(impact factor: 3.867)                             [Cit 1]
  21. Sutton S, Koach J, Tan O, Liu B, Carter DR, Wilmott JS, Yosufi B, Haydu EL, Mann GJ, Thompson JF, Long GV, LIU T, McArthur GA, Zhang XD, Scolyer RA, Cheung BB, and Marshall GM. TRIM16 Inhibits Proliferation and Migration through Regulating Interferon Beta 1 in Melanoma Cells. Oncotarget, 2014; 5(20): 10127-10139 (impact factor:5.008)                             [Cit 4]
  22. Vignarajan S, Xie C, Yao M, Sun Y, Simanainen U, Sved P, LIU T, and Dong Q. Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A₂α via AKT in prostate cancer cells.Oncotarget,2014; 5(15):6289-6299 (impact factor: 5.008)                            [Cit 9]
  23. Shahbazi J, Scarlett CJ, Norris MD, Liu B, Haber M, Tee AE, Carrier A, Biankin AV, Marshall GM, Lock RB, and LIU T.Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. Oncotarget, 2014; 5(12): 4257-4268  (impact factor:5.008)                            [Cit 10]
  24. Liu PY, Erriquez D, Marshall GM, Tee AE, Polly P, Wong M, Liu B, Bell JL, Zhang XD, Milazzo G, Cheung BB, Fox A, Swarbrick A, Hüttelmaier S, Kavallaris M, Perini G, Mattick JS, Dinger ME, andLIU T. Effects of a Novel Long Noncoding RNA, lncUSMycN, on N‐Myc Expression and Neuroblastoma Progression. J Natl CancerInst, 2014;106(7): dju113(impact factor:11.370)                             [Cit 17]
  25. Tee A, Ling D, Nelson C, Atmadibrata B, Dinger ME, Mizukami T, Xu N, Liu PY, Liu B, Cheung BB, Pasquier E, Haber M, Norris MD, Suzuki T, Marshall GM, and LIU T. The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1.Oncotarget, 2014; 5(7):1793-1804 (impact factor:5.008)                 [Cit 26]
  26. Marshall GM, Carter DR, Cheung BB, LIU T, Mateos MK, Meyerowitz JG, and Weiss WA.The prenatal origins of cancer. Nat Rev Cancer,2014; 14(4):277-289 (impact factor:34.244)                            [Cit 30]
  27. Atmadibrata B, Sokolowski N, Zhang L, Wong M, Marshall GM, andLIU T.The novel long noncoding RNA linc00467 promotes cell survival but is down-regulated by N-Myc.PLoS One,2014; 9(2): e88112 (impact factor: 3.057)                             [Cit 8]
  28. Kim PY, Tan O, Diakiw S, Carter D, Sekerye EO, Wasinger VC, LIU T, Kavallaris M, Norris MD, Haber M, Chesler L, Dolnikov A, Trahair TN, Cheung NK, Marshall GM, and Cheung BB. Identification of plasma Complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach. J Proteomics,2014; 96:1-12 (impact factor: 3.867)            [Cit 6]
  29. Sun Y, Liu PY, Scarlett CJ, Malyukova A, Liu B, Marshall GM, MacKenzie KL, Biankin AV, and LIU T. Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc. Oncogene,2014; 33(23):2987-2994 (impact factor:7.932)                            [Cit 11]
  30. Zhang L, Sokolowski N, Atmadibrata B, andLIU T. Histone demethylase JARID1B promotes cell proliferation but is downregulated by N-Myc oncoprotein. Oncol Rep, 2014; 31(4):1935-1939 (impact factor: 2.486)                            [Cit 3]
  31. Lai F, Guo ST, Jin L, Jiang CC, Wang CY, Croft A, Chi MN, Tseng HY, Farrelly M, Atmadibrata B, Norman J, LIU T, Hersey P, and Zhang XD.Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death Dis, 2013;6(4):e655 (impact factor:5.378)                             [Cit 16]
  32. Shahbazi J, Lock R, andLIU T.Tumor protein 53-induced nuclear protein 1 enhances p53 function and represses tumorigenesis.Front Genet, 2013; 4(May):80 (Review) (Impact Factor: n/a)                            [Cit 18]
  33. Kan C-Y, Petti C, Bracken L, Maritz M, Xu N, Yang C, LIU T, Yuan J, Lock RB, and MacKenzie KL. Up-regulation of survivin during immortalization of human myofibroblasts is linked to repression of p16INK4a and confers resistance to oxidative stress. J Biol Chem, 2013; 288(17): 12032-12041 (impact factor: 4.258)                            [Cit 2]
  34. Ye Y, Jin L, Wilmott JS, Hu WL, Yosufi B, Thorne RF, LIU T, Rizos H, Yan XG, Dong L, Tay KH, H-Y Tseng, Guo ST, de Bock CE, Jiang CC, Wang CY, Wu M, Zhang LJ, Hersey P, Scolyer RA, and Zhang XD. PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nat Commun, 2013;4:1508 (impact factor: 11.329)                             [Cit 30]
  35. Wauters E, Sanchez‐Arévalo Lobo VJ, Pinho AV, Mawson A, Wu J, Cowley MJ, Colvin EK, Njicop EN, Sutherland RL, LIU T, Serrano M, Bouwens L, Real FX, Biankin AV, and Rooman I.Sirtuin-1 regulates acinar to ductal metaplasia and supports cancer cell viability in pancreatic cancer. Cancer Res,2013; 73(7):2357-2367 (impact factor: 8.556)                             [Cit 18]
  36. Liu PY, Xu N, Malyukova A, Scarlett CJ, Sun YT, Zhang XD, Ling D, Su SP, Nelson C, Chang DK, Koach J, Tee AE, Haber M, Norris MD, Toon C, Rooman I, Xue C, Cheung BB, Kumar S, Marshall GM, Biankin AV, andLIU T.The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ, 2013;20(3):503-514(impact factor:8.218)                             [Cit 49]
  37. Malyukova A, Brown S, Papa R, O’Brien R, Giles J, Trahair TN, Pozza LD, Sutton R, LIU T, Haber M, Norris MD, Lock RB, Sangfelt O, and Marshall GM.FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation. Leukemia, 2013; 27: 1053-1062 (impact factor:12.104)                               [Cit 12]
  38. Calao M, Sekyere EO, Cui HJ, Cheung BB, Thomas WD, Keating J, Chen JB, Raif A, Jankowski K, Davies NP, Bekkum MV, Chen B, Tan O, Ellis T, Norris MD, Haber M, Kim ES, Shohet JM, Trahair TN, LIU T, Wainwright BJ, Ding HF, and Marshall GM. Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation. Oncogene,2013; 32(31): 3616-3626 (impact factor:7.932)                             [Cit 23]
  39. Ling D, Marshall GM, Liu PY, Xu N, Nelson CA, Iismaa S, and LIU T. Enhancing the anticancer effect of the histone deacetylase inhibitor by activating transglutaminase. Eur J Cancer,2012; 48(17): 3278-3287 (impact factor:6.163)                             [Cit 6]
  40. Liao V, LIU T, and Codd R.Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: Attenuation of potency through resonance effects. Bioorg Med Chem Lett,2012; 22(19): 6200-6204 (impact factor: 2.486)                            [Cit 3]
  41. Tay KH, Jin L, Tseng HY, Jiang CC, Ye Y, Thorne RF, LIU T, Guo ST, Verrills NM, Hersey P, and Zhang XD. Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress. Cell Death Dis, 2012;3(6):e337 (impact factor:5.378)                            [Cit 18]
  42. Marshall GM, Liu PY, Gherardi S, Scarlett CJ, Bedalov A, Xu N, Iraci N, Thomas W, van Bekkum M, Sekyere E, Jankowski K, Trahair T, MacKenzie KL, Haber M, Norris MD, Biankin AV, Perini G, and LIU T. SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability.PLoS Genetics, 2011; 7(6):e1002135 (impact factor:6.661)                            [Cit 68]
  43. Marshall GM, Bell JL, Koach J, Tan O, Kim P, Malyukova A, Thomas W, Sekyere EO, LIUT, Cunningham AM, Tobias V, Norris MD, Haber M, Kavallaris M, and Cheung BB. TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells. Oncogene, 2010; 29(46):6172-6183 (impact factor:7.932)           [Cit 21]
  44. Marshall GM, Gherardi S, Xu N, Neiron Z, Trahair T, Scarlett CJ, Chang DK, Jankowski K, Iraci N, Haber M, Norris M, Keating J, Sekyere E, Jonquieres G, Stossi F, Katzenellenbogen B, Biankin AV, Perini G, andLIU T. Transcriptional up-regulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene, 2010; 29(44):5957-5968 (impact factor:7.932)                            [Cit 43]
  45. Bell E, Chen L, LIU T, Marshall G, Lunec J, and Tweddle DA. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett,2010; 293(2):144-157 (impact factor: 5.992)                             [Cit 47]
  46. Tee AE, Marshall GM, Liu PY, Xu N, Haber M, Norris MD, Lismaa SE, and LIU T. Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation. J Biol Chem, 2010; 285(6):3561-3567 (impact factor: 4.258)                             [Cit 24]
  47. Kuljaca S, LIU T, Dwarte T, Kavallaris M, Haber M, Norris MD, Martin-Caballero J, and Marshall GM. The cyclin-dependent kinase inhibitor, p21WAF1, promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells. Carcinogenesis, 2009; 30(11):1865-1871(impact factor: 5.334)                             [Cit 12]
  48. LIU T, Liu PY, Tee AEL, Haber M, Norris MD, Gleave ME, and Marshall GM. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.Eur J Cancer, 2009; 45(10): 1846-1854(impact factor:6.163)                            [Cit 26]
  49. LIU T, Liu PY, and Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res, 2009; 69(5): 1702-1705(impact factor: 8.556)                            [Cit 191]
  50. LIU T, Tee AEL, Porro A, Smith SA, Dwarte T, Pei YL, Iraci N, Sekyere E, Haber M, Norris MD, Diolaiti D, Della Valle G, Perini G, and Marshall GM. Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc Natl Acad Sci USA, 2007; 104(47): 18682-18687(impact factor: 9.423)             [Cit 62]
  51. Kuljaca S, LIU T, Tee AEL, Haber M, Norris MD, Dwarte T, and Marshall GM. Enhancing the anti-angiogenic action of histone deacetylase inhibitors. Mol Canc,2007; 6:68(impact factor: 5.888)                             [Cit 21]
  52. LIU T, Kuljaca S, Tee A, and Marshall GM.Histone deacetylase inhibitors: Multifunctional anticancer agents. Cancer Treat Rev, 2006; 32(3): 157-165(impact factor: 7.983)                            [Cit 160]
  53. LIU T, Bohlken A, Kuljaca S, Lee M, Nguyen T, Smith S, Cheung B, Morris MD, Haber M, Holloway AJ, Bowtell DD, and Marshall GM. The retinoid anticancer signal: Mechanisms of target gene regulation.Brit J Cancer,2005; 93(3): 310-318(impact
    factor: 5.569)                            [Cit 30]
  54. Bauskin AR, Brown DA, Junankar S, Rasiah KK, Eggleton S, Hunter M, LIU T, Smith D, Kuffner T, Pankhurst GJ, Johnen H, Russell PJ, Barret W, Stricker PD, Grygiel JJ, Kench JG, Henshall SM, Sutherland RL,and Breit SN.The propeptide mediates formation of stromal stores of PROMIC-1: Role in determining prostate cancer outcome. Cancer Res,2005; 65(6):  2330-2336(impact factor: 8.556)                             [Cit 72]
  55. LIU T, Bauskin AR, Zaunders J, Brown DA, Pankurst S, Russell PJ, and Breit, SN.Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res,2003; 63(16): 5034-5040(impact factor: 8.556)                              [Cit 128]
  56. Brown DA, Ward RL, Buckhaults P, LIU T, Romans KE, Hawkins NJ, Bauskin AR, Kinzler KW, Vogelstein B, and Breit SN. MIC-1 serum level and genotype: Associations with progress and prognosis of colorectal carcinoma . Clin Cancer Res,2003; 9(7): 2642-2650(impact factor: 8.738)                             [Cit 142]
  57. Welsh JB, Sapinoso LM, Kern SG, Brown DA, LIU T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ, Sutherland RL, Breit SN, Moskaluk CA, Frierson HF Jr,and Hampton GM.Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum.Proc Natl Acad Sci USA,2003; 100(6): 3410-3415(impact factor: 9.423)                             [Cit 246]
  58. Brown DA, Breit SN, Buring J, Fairlie WD, Bauskin AR, LIU T, and Ridker PM. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: A nested case-control study. Lancet,2002; 359(9324):  2159-2163(impact factor: 44.002)                             [Cit 122]
  59. Brown DA, Bauskin AR, Fairlie WD, Smith MD, LIU T, Xu N, and Breit SN.Antibody-based approach to high-volume genotyping for MIC-1 polymorphism. BioTechniques, 2002; 33(1): 118-120(impact factor: 2.298)                             [Cit 38]
  60. LIU T, and Tracey DJ. ATP P(2X) receptors play little role in the maintenance of neuropathic hyperalgesia.NeuroReport,2000; 11(8): 1669-1672(impact factor: 1.343)                            [Cit 14]
  61. LIU T, Van Rooijen N, and Tracey DJ. Depletion of macrophages reduces axonal degeneration and hyperalgesia following nerve injury. Pain,2000; 86(1-2): 25-32 (impact factor: 5.557)                            [Cit 133]
  62. LIU T, Knight KR, and Tracey DJ. Hyperalgesia due to nerve injury-role of peroxynitrite. Neuroscience,2000; 97(1): 125-131(impact factor: 3.231)                            [Cit 27]

cancer-research Journal Flyer